Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

67.44EUR
2:15pm IST
Change (% chg)

€-1.27 (-1.85%)
Prev Close
€68.71
Open
€67.85
Day's High
€68.00
Day's Low
€67.04
Volume
546,396
Avg. Vol
3,296,198
52-wk High
€101.10
52-wk Low
€67.04

SASY.PA

Chart for SASY.PA

About

Sanofi SA is a healthcare company focused on patient needs and engaged in the research, development, manufacture and marketing of healthcare products. The Company is organized around three principal activities: Pharmaceuticals, Human Vaccines via Sanofi Pasteur, and Animal Health via Merial. The Company invests in emerging... (more)

Overall

Beta: 0.79
Market Cap(Mil.): €90,015.48
Shares Outstanding(Mil.): 1,305.71
Dividend: 2.93
Yield (%): 4.13

Financials

  SASY.PA Industry Sector
P/E (TTM): 17.35 31.59 38.02
EPS (TTM): 3.97 -- --
ROI: -- 14.92 14.26
ROE: -- 15.54 15.06
Search Stocks

EU mergers and takeovers (Feb 10)

BRUSSELS, Feb 10 The following are mergers under review by the European Commission and a brief guide to the EU merger process:

1:17am IST

UPDATE 3-Regeneron sees gradual adoption of cholesterol drug Praluent

* Shares down 5.3 pct at $369.77 (Adds details from conference call, analyst comment)

09 Feb 2016

UPDATE 2-Sanofi pledges stable 2016 earnings

* Proposes 2.93 euro dividend (Adds details, comment, share price)

09 Feb 2016

BRIEF-Zealand Pharma Q4 lixisenatide (Lyxumia) royalty rev up 31 pct at DKK 8.1 mln

* Q4 royalty revenue from Sanofi's sales of lixisenatide (Lyxumia) outside US up at 8.1 million Danish crowns / 1.1 million euros ($1.23 million), up 15 pct over Q3, up 31 pct over Q4 2014

09 Feb 2016

Sanofi pledges stable 2016 earnings despite headwinds

PARIS, Feb 9 Sanofi reported lower fourth-quarter earnings on Tuesday, hurt by declining sales in key divisions such as diabetes, oncology and prescription drugs, but said it expected 2016 earnings per share to be stable.

09 Feb 2016

EU mergers and takeovers (Feb 8)

BRUSSELS, Feb 8 The following are mergers under review by the European Commission and a brief guide to the EU merger process:

08 Feb 2016

EU mergers and takeovers (Feb 5)

BRUSSELS, Feb 5 The following are mergers under review by the European Commission and a brief guide to the EU merger process:

05 Feb 2016

EU mergers and takeovers (Feb 4)

BRUSSELS, Feb 4 The following are mergers under review by the European Commission and a brief guide to the EU merger process:

04 Feb 2016

EU mergers and takeovers (Feb 3)

BRUSSELS, Feb 3 The following are mergers under review by the European Commission and a brief guide to the EU merger process:

03 Feb 2016

WRAPUP 7-First U.S. Zika virus transmission reported, attributed to sex

AUSTIN, Texas, Feb 2 The first known case of Zika virus transmission in the United States was reported in Texas on Tuesday by local health officials, who said it likely was contracted through sex and not a mosquito bite, a day after the World Health Organization declared an international public health emergency.

03 Feb 2016

Earnings vs. Estimates

Search Stocks